Long-term non-progression in HIV infection: Clinico pathological issues

Journal of Infection

Volumn 38, Issue 2, 1999, Pages 67-70

  Rowland Jones, Sarah ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE COURSE; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOLOGY; SHORT SURVEY; VIROLOGY;

EID: 0032918540     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(99)90070-1     Document Type: Article

References (26)

1. Koup RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of virernia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68: 4650-4655.
2. Clerici M and Shearer G. A Th1 → Th2 switch is a critical step in the aetiology of HIV infection. Immunol Today 1993; 14: 107-111.
3. Rowland-Jones SL, Tan R and McMichael AJ. The role of cellular immunity in protection against HIV infection. Adv Immunol 1997; 65: 277-346.
4. Dragic T, Litwin V, Allaway GP et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
5. Bleul CC, Wu L, Hoxie JA, Springer TA and Mackay CR. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci 1997; 94: 1925-1930.
6. Cocchi F, DeVico AL, Garzino DA et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
7. Cao Y, Qin L, Zhang L, Safrit J and Ho DD. Virological and immunological characterisation of long-term survivors of HIV-1 infection. New Engl J Med 1995; 332: 201-208.
8. Pantaleo C, Vaccarezza M, Graziosi C, Cohen OJ and Fauci AS. Antiviral immunity in HIV-1 infected long-term non-progressors. Sem Virol 1996; 7: 131-138.
9. Xiao L, Rudolph DL, Owen SM, Spira TJ and Lal RB. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998; 12: F137-143.
10. Dyer WB, Geczy AF, Kent SJ et al. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS 1997; 11: 1565-1574.
11. Liegler TJ, Yonemoto W, Elbeik T et al. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. J Infect Dis 1998; 178: 669-679.
12. Rinaldo C, Huang X-L, Fan Z et al. High levels of anti-HIV-1 memory CTL activity and low viral load are associated with lack of disease in HIV-1-infected long-term non-progressors. J Virol 1995; 69: 5838-5842.
13. Harrer T, Harrer E, Kalams SA et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. Aids Res Hum Retroviruses 1996; 12: 585-592.
14. Rosenberg ES, Billingsley JM, Cajiendo A et al. Vigorous HIV-1-specific CD4+ T-cell responses associated with control of viraemia. Science 1997; 278: 1447-1450.
15. Montefiori DC, Pantaleo G, Fink LM et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996; 173: 60-67.
16. Deacon NJ, Tsykin A, Smith SK et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-991.
17. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK and Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258: 1938-1941.
18. Whittle HC, Ariyoshi K and Rowland-Jones S. HIV-2 and T cell recognition. Curr Opin Immunol 1998; 10: 382-387.
19. Klein MR, Keet IP, D'Amaro J et al. Associations between HLA frequencies and pathogenic features of human immunodeficiency virus type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J Infect Dis 1994; 169: 1244-1249.
20. Kaslow RA, Carrington M, Apple R et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat-Med 1996; 2: 405-411.
21. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study. Multicenter AIDS Cohort Study. Multicenter Hemophilia Cohort Study. San Francisco City Cohort, ALIVE Study. Science 1996; 273: 1856-1862.
22. Smith MW, Dean M, Carrington M et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). ALIVE Study. Science 1997; 277: 959-965.
23. Kostrikis L, Huang Y, Moore JP et al. A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4: 350-353.
24. McDermott DH, Zimmerman PA, Guignard F et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352: 866-870.
25. Mummidi S, Ahuja SS, Gonzalez E et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998; 4: 786-793.
26. Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study. Hemophilia Growth and Development Study (HGDS). Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279: 389-393.